China has officially started plasma transfusion for treating coronavirus infected patients and other countries have not started yet.
Japanese pharmaceutical company Takeda said in a press release that plasma derived-therapies have been effective in the treatment of severe acute viral respiratory infections and may be a treatment option for COVID-19. It added that research had been initiated for the development of an anti-SARS-CoV-2 hyperimmune serum.
A clinical trial report by the U.S. National Libray of Medicine says that as of now, there is no effective antiviral drugs and vaccines available against the virus SARS-CoV-2 and that it is an observational study. The investigators collected the clinical information and clinical outcomes of the COVID-19 patients using anti-2019-nCoV inactivated convalescent plasma. The report also added that the purpose of the study was to evaluate the efficacy and safety of anti-2019-nCoV inactivated convalescent plasma in the treatment of COVID-19 pneumonia.
As of now, China has started using convalescent plasma from recovered patients to treat infected patients, and in other countries, research and development are being conducted.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.